Compare GIB & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GIB | ABVX |
|---|---|---|
| Founded | 1976 | 2013 |
| Country | Canada | France |
| Employees | 94000 | N/A |
| Industry | Professional Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 11.9B |
| IPO Year | 1999 | 2022 |
| Metric | GIB | ABVX |
|---|---|---|
| Price | $69.35 | $95.06 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 13 |
| Target Price | $112.00 | ★ $131.31 |
| AVG Volume (30 Days) | 306.0K | ★ 1.1M |
| Earning Date | 04-29-2026 | 03-23-2026 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.33 | $52.14 |
| Revenue Next Year | $2.96 | $4,132.27 |
| P/E Ratio | $13.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $59.63 | $69.81 |
| 52 Week High | $95.20 | $148.83 |
| Indicator | GIB | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
CGI is a Canada-based IT-services provider with an embedded position in North America and Europe. The company is one of the major IT suppliers to different levels of government around the world. It offers a broad portfolio of services such as consulting, systems integration, application maintenance, and business process services to governments and the private sector. With offices in over 40 countries, CGI follows a balanced global delivery model with most consultants in client proximity.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.